Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903
Theravance Biopharma has dosed first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903. (Credit: Daniel Roberts from Pixabay)
Theravance Biopharma has dosed first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903. (Credit: Daniel Roberts from Pixabay)